Everything below concerns SR9009. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2026-06-19. Numbers and descriptions here follow the published literature rather than marketing material.
SR9009 is frequently discussed in fitness and research-chemical contexts, yet it has no approved medical indication. Regulatory agencies have not authorized it for human use, and it is not a standard prescription drug. Some sports organizations list it as a prohibited substance because of its potential performance-enhancing properties. Published human data are sparse, so claims about its effects in people often rely on animal models or anecdotal reports. Quality and identity of online materials can vary widely.
SR9009 is a synthetic small molecule studied as a REV-ERB agonist. REV-ERBα and REV-ERBβ are nuclear receptors that help regulate circadian rhythms and metabolic gene expression. The compound was identified in academic screening efforts to find synthetic ligands for these receptors. In cell and animal studies, SR9009 alters transcription of genes involved in lipid and glucose metabolism, and it can shift circadian behavior. It is not an approved therapeutic agent.
Mechanistically, SR9009 binds the ligand-binding domain of REV-ERBα/β and enhances recruitment of corepressor complexes. This represses target genes rather than activating them. Because REV-ERB proteins normally compete with ROR proteins at shared response elements, the net effect depends on tissue and timing. Researchers use SR9009 to probe how nuclear receptor signaling links the clock to metabolism, inflammation, and muscle biology. Findings are largely preclinical, and the precise contribution of each receptor subtype remains under study.
Regulatory agencies have not approved SR9009 for human therapeutic use. It is typically sold as a research chemical with labels stating that it is not for human consumption. The World Anti-Doping Agency prohibits the substance in sport, generally under the category of non-approved substances. Customs and national laws may restrict importation, sale, or possession. Product quality and legal status can vary by country and vendor, and therapeutic claims are not permitted in regulated advertising because the compound lacks approval.
Several misconceptions surround SR9009. It is often described as a SARM, a steroid, or an exercise pill, but its known target is the REV-ERB receptor family. Rodent studies have examined exercise capacity and metabolic markers, yet human outcomes remain unproven. Oral bioavailability appears low in animals, and human pharmacokinetics are not well characterized. Online products may contain impurities or different compounds, so identity and purity testing are important for research use.
Analytical chemists detect SR9009 with liquid chromatography-tandem mass spectrometry, commonly abbreviated LC-MS/MS. Sample preparation may involve protein precipitation, liquid-liquid extraction, or solid-phase extraction before analysis. Laboratories can target the parent compound or its metabolites, depending on the matrix and the purpose of testing. Anti-doping methods require sensitive and specific assays because concentrations in biological samples can be low. Reference standards and validated methods are essential for reliable identification and quantification.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic REV-ERB agonist | Small-molecule ligand; not a hormone or peptide |
| Molecular formula | C20H24ClN3O4S | Reported for the free base |
| CAS Registry Number | 1379686-30-2 | Unique chemical identifier |
| Common synonyms | SR9009; stenabolic | Stenabolic is informal and not an official name |
| Reported targets | REV-ERBα and REV-ERBβ | Nuclear receptors linked to circadian and metabolic regulation |
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms, lipid metabolism, and inflammatory gene expression. In cell and animal experiments, SR9009 alters transcription of clock-controlled genes and metabolic pathways. The compound is not a hormone and does not resemble classical steroid structures. Its activity depends on binding to the ligand-binding domain of REV-ERB, where it can modify corepressor recruitment.
Research interest in SR9009 grew from studies of circadian biology and metabolic disease. Preclinical reports describe effects on exercise capacity, muscle metabolism, and blood lipid levels in rodents, but these findings come from controlled laboratory settings. The compound has low oral bioavailability in animals, which limits systemic exposure after swallowing. Investigators often use injected routes in experiments to achieve measurable plasma concentrations. Human clinical data are sparse, no approved therapeutic product exists, and whether animal effects translate to humans remains an open question.
Analytical identification of SR9009 typically relies on liquid chromatography coupled with tandem mass spectrometry. In biological samples, researchers first separate the compound from matrix components using protein precipitation, liquid-liquid extraction, or solid-phase extraction. High-performance liquid chromatography with ultraviolet detection and nuclear magnetic resonance spectroscopy can support structural confirmation of reference materials. Because SR9009 is a small, relatively lipophilic molecule, reverse-phase columns and acidic mobile phases are common. Laboratories often include isotope-labeled internal standards to improve quantification and to correct for ion suppression.
Stability depends on physical form, temperature, light exposure, and solvent. Solid SR9009 is generally stored cold and dry, with protection from light to limit degradation. Dimethyl sulfoxide stocks are common for laboratory work, but repeated freeze-thaw cycles can reduce compound integrity. Aqueous solutions may be less stable than organic stocks, and the ethyl ester in the structure can be susceptible to hydrolysis under certain conditions. Researchers typically validate storage conditions and recheck purity before quantitative experiments, especially when using archived material.
Regulatory treatment of SR9009 varies by country and region. It is not approved as a pharmaceutical, and several jurisdictions restrict its sale for human consumption. Some authorities classify it as a research chemical, a prescription-only substance, or a prohibited performance-enhancing agent in sport. Purchasers may encounter certificates of analysis, but these documents do not guarantee identity, purity, or legality. In research settings, institutional safety reviews and controlled procurement help ensure that materials are handled under appropriate oversight. The absence of harmonized rules means that legal status can change and requires verification.
SR9009 binds REV-ERB receptors and alters their repressive activity on target genes. This action can change transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. In rodent studies, treated animals have shown changes in muscle oxidative capacity and exercise performance, though effects vary by dose, duration, and model. The precise molecular steps connecting receptor binding to whole-body outcomes are still an active area of investigation. Findings in animals do not automatically translate to humans.
Because REV-ERB receptors are core clock components, SR9009 has been examined for effects on daily rhythms as well as metabolism. Research has explored whether the compound can shift or reinforce circadian gene expression in tissues such as liver and muscle. Some studies report improved metabolic markers in obese or diabetic mice, while others show context-dependent responses. Questions remain about which effects are direct, which are secondary to timing, and how they might differ across species.
SR9009 is a synthetic small molecule that acts on the nuclear receptors REV-ERBα and REV-ERBβ. These receptors are part of the circadian clock machinery and normally repress transcription of certain target genes. In laboratory research, SR9009 is used as a chemical tool to study how REV-ERB activity influences metabolism, inflammation, and daily biological rhythms. The compound is not an approved medicine, and its effects in humans remain largely uncharacterized. It is often described as an investigational agent rather than a therapeutic product.
REV-ERB proteins typically suppress gene expression by recruiting corepressor complexes to DNA response elements. SR9009 binds these receptors and strengthens that repressive action in cell-based assays. Studies in rodents have reported changes in lipid handling, mitochondrial function, and exercise capacity after treatment. Such findings are often cited as evidence for metabolic effects, but species differences and limited pharmacokinetic data make direct translation to humans uncertain. Researchers continue to examine which effects are robust and which depend on specific experimental conditions.
SR9009 is frequently discussed alongside other REV-ERB ligands, including synthetic agonists and natural heme-related molecules. Its selectivity for REV-ERB over related nuclear receptors has been measured in binding and reporter assays, though off-target activity at higher concentrations is possible. The compound is prohibited in sport by the World Anti-Doping Agency, and it is not approved for any medical use in major jurisdictions. Products sold online may be labeled as research chemicals, and their identity and purity are not guaranteed by regulatory review.
Co-translational O-GlcNAc has been identified on Sp1 and Nup62. This modification suppresses co-translational ubiquitination and thus protects nascent polypeptides from proteasomal degradation. Similar protective effects of O-GlcNAc on full-length Sp1 have been observed. It is unknown if this pattern is universal or only applicable to specific proteins. Protein phosphorylation is often used as a mark for subsequent degradation. Tumor suppressor protein p53 is targeted for proteasomal degradation via COP9 signalosome-mediated phosphorylation of T155. O-GlcNAcylation of p53 S149 has been associated with decreased T155 phosphorylation and protection of p53 from degradation. β-catenin O-GlcNAcylation competes with T41 phosphorylation, which signals β-catenin for degradation, stabilizing the protein. O-GlcNAcylation of the Rpt2 ATPase subunit of the 26S proteasome has been shown to inhibit proteasome activity. Testing various peptide sequences revealed that this modification slows proteasomal degradation of hydrophobic peptides, degradation of hydrophilic peptides does not appear to be affected. This modification has been shown to suppress other pathways that activate the proteasome such as Rpt6 phosphorylation by cAMP-dependent protein kinase. OGA-S localizes to lipid droplets and has been proposed to locally activate the proteasome to promote remodeling of lipid droplet surface proteins.
Many mammals communicate by vocalizing. Vocal communication serves many purposes, including in mating rituals, as warning calls, to indicate food sources, and for social purposes. Males often call during mating rituals to ward off other males and to attract females, as in the roaring of lions and red deer. The songs of the humpback whale may be signals to females; they have different dialects in different regions of the ocean. Social vocalizations include the territorial calls of gibbons, and the use of frequency in greater spear-nosed bats to distinguish between groups. The vervet monkey gives a distinct alarm call for each of at least four different predators, and the reactions of other monkeys vary according to the call. For example, if an alarm call signals a python, the monkeys climb into the trees, whereas the eagle alarm causes monkeys to seek a hiding place on the ground. Prairie dogs similarly have complex calls that signal the type, size, and speed of an approaching predator. Elephants communicate socially with a variety of sounds including snorting, screaming, trumpeting, roaring and rumbling. Some of the rumbling calls are infrasonic, below the hearing range of humans, and can be heard by other elephants up to 6 miles (9.7 km) away at still times near sunrise and sunset.
== Function == This locus encodes a protein that may play a role in the cellular response to arterial injury through involvement in vascular remodeling. Mutations at this locus have been associated with Barrett's esophagus and esophageal adenocarcinoma. Alternatively, spliced transcript variants have been described.
== External links == Information Digest, 2022–2023 (NUREG-1350, Volume 34), NRC Reactors Designed by Argonne National Laboratory: Fast Reactor Technology Argonne pioneered the development of fast reactors and is a leader in the development of fast reactors worldwide. See also Argonne's Nuclear Science and Technology Legacy. The Changing Need for a Breeder Reactor by Richard Wilson at The Uranium Institute 24th Annual Symposium, September 1999 Experimental Breeder Reactor-II (EBR-II): An Integrated Experimental Fast Reactor Nuclear Power Station International Thorium Energy Organisation – www.IThEO.org A Path Forward for the LMFBR Plutonium Fuel Fabrication by Argonne National Laboratory on YouTube
Sources: en.wikipedia.org
== Real-life analogues == The phase transitions without any thermal effect and into the state of lower entropy described in the book are purely fictional and impossible according to current theories of physics. In the assumption that the phase transition was described inaccurately and has thermal effects (which were not described within the novel), it would have happened without any outside intervention. The initial seed being nucleated spontaneously was due to fluctuations that are always present, the same way that the ordinary liquid-solid transitions happen. Supercooling is only possible when nucleation cannot occur, which is difficult in normal circumstances due to natural impurities in water. While multiple polymorphs of ice exist, none have the properties described in the novel, and none are stable at standard temperature and pressure. The real Ice IX has none of the properties of Vonnegut's creation, and can exist only at extremely low temperatures and high pressures. Ice VII is stable at room temperature, but only under very high pressures. The ice-nine-like phenomenon has occurred with a few other kinds of crystals, called "disappearing polymorphs". In these cases, a new variant of a crystal has been introduced into an environment, replacing many of the older form crystals with its own form. One example is the anti-AIDS medicine ritonavir, where the newer polymorph destroyed the effectiveness of the drug in solid form, requiring a change to the less efficacious liquid form.
== Other products produced == The main products of malolactic fermentation are lactic acid, diacetyl, acetic acid, acetoin, and various esters. The amount and exact nature of these products depends on the species/strain of LAB conducting the malolactic fermentation and the condition influencing that wine (pH, available nutrients, oxygen levels, etc.). Some strains of O. oeni can synthesize higher alcohols which can contribute to fruity notes in the aroma of the wine. Additionally, some strains of the bacterium have beta-glucosidase enzymes that can break down monoglucosides which are aroma compounds attached to a sugar molecule. When the sugar component is cleaved, the rest of the compound becomes volatilized, meaning it can potentially be detected in the aroma bouquet of the wine. In the early 21st century, some strains of O. oeni were shown to use acetaldehyde by breaking it down into ethanol or acetic acid. While this may help for wines with excessive levels of acetaldehyde, for red wines, it can also destabilize the color of the wine by interfering with acetaldehyde's reaction with anthocyanins to create polymeric pigments that help create a wine's color.
In January 2018, a class action lawsuit was filed against LifeVantage in Connecticut alleging that the company and its chief executive officer Darren Jensen, chief sales officer Justin Rose, and chief marketing officer Ryan Goodwin were operating an illegal pyramid scheme in violation of the RICO Act, federal securities laws, and the Connecticut Unfair Trade Practices Act.
Sources: en.wikipedia.org
=== Nancy Bartlett === Nancy Lynn Bartlett is played by Sandra Bernhard. Nancy is a part owner of the Lanford Lunch Box. She marries Arnie Thomas, but — after he eventually leaves her — she comes out as a lesbian. She frequently is seen dating women; her first girlfriend Marla is played by Morgan Fairchild. Nancy is never ashamed of her promiscuity, nor does she ever show any self-consciousness about her unusual behavior. She is one of the most self-confident characters in the series, often even more than Roseanne. Her tendency toward self-absorption seems to only be quelled while dating a woman or being around Jackie. Nancy turns out to be a loyal good friend to both Roseanne and Jackie throughout the series; however, she doesn't hesitate to reprimand them for their selfishness and cruelty when they treat their mother, Bev, so harshly that Bev ends up crying about it for days afterward while Nancy gives her support. Nancy appeared in a revival-era episode in 2018 in season 10, but did not appear on The Conners.
=== Non-competitive === In non-competitive inhibition the binding of the inhibitor to the enzyme reduces its activity but does not affect the binding of substrate. This type of inhibitor binds with equal affinity to the free enzyme as to the enzyme-substrate complex. It can be thought of as having the ability of competitive and uncompetitive inhibitors, but with no preference to either type. As a result, the extent of inhibition depends only on the concentration of the inhibitor. Vmax will decrease due to the inability for the reaction to proceed as efficiently, but Km will remain the same as the actual binding of the substrate, by definition, will still function properly.
=== Civil rights === Bhutto Zardari has repeatedly defended the rights of minorities in Pakistan. On 4 December 2012, in a statement responding to reports about the demolition of a Hindu temple in Karachi and a desecration of an Ahmadiyya graveyard in Lahore he said, "Our forefathers did not sacrifice their lives for an intolerant, extremist, sectarian, and authoritarian Pakistan. I appeal to all of you to rise up and defend Jinnah's Pakistan. My party and I will stand by you, shoulder to shoulder." During a cake cutting ceremony for Christmas in Karachi, on 25 December 2018, Bhutto Zardari said that he PPP is the custodian of social justice, parity, religious, and interfaith harmony in the country and its advocacy for the prevalence of peace and tranquility across the world is heavily established. At the memorial for the 7th death anniversary of former Federal Minister of Interfaith Harmony, Shahbaz Bhatti on 3 March 2018, Bhutto Zardari said, "May I take this opportunity to say that we share the concerns over the misuse of blasphemy laws. This is the concern of not only the Christian community but of all of us. It is my concern too. These laws have been used as a tool by extremists to settle personal scores. They have been used to grab the properties of Christians and other non-Muslims. The blasphemy laws carry the mandatory death penalty. We must prevent their misuse. We will." On 29 September 2019, he visited the Hindus in Ghotki and the Sacho Satram Dham temple which was desecrated in the 2019 Ghotki riots and condemned the attack.
Sources: en.wikipedia.org
SR9009 is a synthetic compound investigated as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is used in preclinical research on circadian rhythm and metabolism. It is not an approved drug.
No. It has no approved medical indication, and human safety and efficacy data are limited. It appears in research chemical markets and is banned by some sports authorities.
Natural ligands include heme and certain metabolites; SR9009 is a synthetic small molecule with higher potency and selectivity in some assays. Its effects depend on cell type and timing. It is not a naturally occurring compound.
Legality depends on the country and the intended use. In many places it is not approved as a medicine and may be sold only as a research chemical. Importation or possession can be restricted, and sports organizations prohibit it.